Sophie Ndaw and Aurélie Remy Abstract: Antineoplastic drugs used in the treatment of cancers have an intrinsic toxicity, because of their genotoxic, teratogenic, and carcinogenic properties. Their use is recognized as an occupational hazard for healthcare...
WHAT IS CYTOPREVENT?
A group of International Experts dedicated to changing practices to reduce potential contamination risks from occupational exposure to hazardous drugs on healthcare professionals.
Follow CytoPrevent on Twitter!
WHAT’S NEW ON CYTOPREVENT?
Hazardous Drug Safety: Clarifying the confusion about closed systems
Risks associated with exposure to hazardous drugs (HDs) such as chemotherapy, have been well doc-umented over the past two decades and include miscar-riages and infertility, as well as an increased possibility of developing cancer. Nurses administering HDs are at a high risk for exposure as IV tubing is prone to drip-ping when disconnected…
ISOPP Standards for the Safe Handling of Cytotoxics
Since the initial release of the International Society of Oncology Pharmacy Practitioners (ISOPP) Standards for the Safe Handling of Cytotoxic Drugs in 2007, much has evolved in oncology pharmacy. Safe handling practices have been refined and new hazardous agents have been discovered and developed for treatment to pose new challenges for workers caring for their patients…
Closed safety system for administration (CSSA): proposal for a new cytotoxic chemotherapy acronym
Seth Eisenberg – Exposure to cytotoxic chemotherapy can result in acute and chronic conditions including nausea, headaches, rashes, miscarriages, infertility and genetic aberrations…
EP calls for action: strengthening Europe in the fight against cancer
On 9 December 2021, Parliament’s Special Committee on Beating Cancer adopted its final proposals on how to strengthen the EU’s role in the fight against cancer. They include the following…
Stop Cancer at Work Campaign welcomes progress made in protecting workers from cancer and reproductive problems at work
Press Release - 16 December 2021 The Stop Cancer at Work Campaign today welcomes the provisional political agreement by the European Parliament and European Council to include for the first time greater protection and reference to reprotoxic substances and...
WHO – Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
Background The toxic effects of antineoplastic drugs used for cancer treatment have been well known since their introduction in the 1940s. However, beyond the patient safety concerns arising from the necessary therapeutic use of these drugs, the occupational risks to...
EU to improve protection of workers from dangerous chemical substances
The Council presidency and the European Parliament have reached a provisional deal to update the carcinogens and mutagens directive, an EU law to protect workers from risks related to exposure to carcinogenic and mutagenic substances.
USP800 in brief – USP800 en résumé
What is a CSTD? Does USP 800 require the use of CSTD’s for compounding HD’s? Does USP 800 require the use of CSTD’s for administering HD’s? Why do nurses need to use a CSTD when administering chemo?